PatentJun 25, 2026, 07:36 AM
Incannex Secures U.S. Patent for IHL-42X in Obstructive Sleep Apnoea
AI Summary
Incannex Healthcare Inc. announced that the USPTO granted a key U.S. patent for its IHL-42X composition and therapeutic methods for Obstructive Sleep Apnoea (OSA). This patent, with a baseline expiry of July 9, 2040, significantly strengthens the company's intellectual property and enhances the commercial value of IHL-42X. The company is also nearing patient recruitment for its DReAMzz Phase 2 dose optimization study, which aims to refine dosing for the planned Phase III development.
Key Highlights
- Incannex Healthcare Inc. secured a U.S. patent grant for IHL-42X for Obstructive Sleep Apnoea (OSA).
- The patent covers the proprietary IHL-42X composition and its therapeutic methods for OSA treatment.
- The patent has a baseline expiry date of July 9, 2040, with potential for further extension.
- The grant significantly strengthens Incannex's intellectual property portfolio and commercial value of IHL-42X.
- IHL-42X is being developed as a novel oral combination therapy for OSA, a condition with unmet medical need.
- The DReAMzz Phase 2 dose optimization study for IHL-42X is nearing patient recruitment.
- The DReAMzz study aims to refine dosing and strengthen the design of the planned Phase III development program.
Price Impact
More from IXHL